Differential Diagnosis and Work-Up for Monocytosis with Thrombocytosis
When encountering a patient with both elevated monocytes and platelets, you must systematically exclude chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia (ET), while ruling out secondary/reactive causes before pursuing expensive molecular testing.
Primary Differential Diagnosis
The combination of monocytosis and thrombocytosis narrows your differential to:
Malignant Causes (Priority)
- Chronic Myelomonocytic Leukemia (CMML) - most important to exclude
- Myeloproliferative Neoplasms with monocytosis (ET, PV, PMF) - 21% of PV and 17% of PMF patients have monocytosis 1
- MDS/MPN overlap syndromes
- Other myeloid malignancies (AML with monocytic differentiation, MDS)
Secondary/Reactive Causes
- Active malignancy (solid tumors) - strongly associated with secondary thrombocytosis 2
- Chronic inflammatory diseases - associated with both findings 2
- Infections - particularly chronic infections
- Iron deficiency anemia - associated with secondary thrombocytosis 2
- Post-splenectomy state - causes both findings 2
Algorithmic Work-Up Approach
Step 1: Clinical Assessment (Specific Details)
History to obtain:
- Thrombosis history (arterial thrombosis predicts ET) 2
- Active malignancy (predicts secondary thrombocytosis) 2
- Chronic inflammatory conditions (IBD, rheumatologic disease) 2
- Splenectomy history 2
- Infectious symptoms (fever, night sweats, weight loss >10% in 6 months) 3
- Smoking status 4
- Duration of monocytosis (≥3 months suggests clonal) 3
Physical examination specifics:
- Spleen size (measure cm below left costal margin) 3
- Cutaneous lesions (monocytic infiltration) 3
- Signs of bleeding or thrombosis
Step 2: Initial Laboratory Testing
Complete blood count with differential:
- Absolute monocyte count - CMML requires >1×10⁹/L persistently 3
- Platelet count - thrombocytosis defined as ≥450×10⁹/L 2
- Hemoglobin and MCV - higher Hgb and MCV favor ET over secondary causes 2
- WBC and neutrophil count - elevated in secondary thrombocytosis 2
- RDW and MPV - higher values favor ET 2
Additional blood tests:
- Ferritin - iron deficiency is a common secondary cause 2
- Inflammatory markers (CRP, ESR)
- LDH - elevated suggests myeloproliferative process 4
Peripheral blood smear examination:
Step 3: Exclude Secondary Causes Before Expensive Testing
Critical point: Active malignancy, chronic inflammatory disease, splenectomy, and iron deficiency strongly predict secondary thrombocytosis and should be addressed first 2. Do not proceed to molecular testing if clear secondary causes are present and can be treated.
Step 4: Bone Marrow Evaluation (If Secondary Causes Excluded)
Bone marrow aspiration and biopsy:
- Blast percentage - must be <20% for CMML 3
- Dysplasia assessment in all lineages 3
- Megakaryocyte morphology - ET shows increased mature-appearing megakaryocytes in loose clusters 5
- Fibrosis grading - exclude primary myelofibrosis 4
Store bone marrow sample for molecular analysis if available 3
Step 5: Cytogenetic and Molecular Testing
Mandatory exclusions per WHO criteria:
Cytogenetics:
- Philadelphia chromosome/BCR-ABL1 - must be negative to diagnose CMML 3
- PDGFRA/PDGFRB rearrangements - exclude if eosinophilia present 3
- Look for abnormalities of chromosome 7, trisomy 8, complex karyotype 3
Molecular testing (high yield):
For MPN diagnosis (ET/PV/PMF):
- JAK2 V617F - present in ~60% of ET, virtually all PV 4, 5
- CALR mutations (exon 9) - present in 60-80% of JAK2/MPL-negative ET 4, 5
- MPL mutations - present in ~5% of ET 4, 5
- Note: ~80% of ET patients express one of these three driver mutations in mutually exclusive manner 5
For CMML diagnosis:
- TET2, SRSF2, ASXL1 - absence of these mutations has ≥90% negative predictive value for CMML 6
- NRAS, KRAS, CBL - frequently mutated in CMML 3
- 93% of CMML patients carry at least one somatic mutation in recurrently mutated genes 3
Additional prognostic mutations:
- TET2, ASXL1, DNMT3A, SF3B1 - present in ~50% of ET patients 5
- SRSF2 - associated with unfavorable outcomes in MPN with monocytosis 1
- ASXL1 - associated with monocytosis in PMF 1
Step 6: Flow Cytometry (Adjunctive)
Monocyte immunophenotyping:
- Aberrant CD11b/HLA-DR, CD36/CD14 ratios 3
- Abnormal CD13, CD14, CD16, CD33, CD36, CD64 intensity 3
- CD56 overexpression 3
- Note: None are specific for CMML but support clonal process 3
Monocyte partitioning can help distinguish CMML from reactive causes 7, 6
Diagnostic Criteria Application
For CMML (WHO 2008 criteria) 3:
- Persistent monocytosis >1×10⁹/L
- No Philadelphia chromosome or BCR-ABL1
- No PDGFRA/PDGFRB rearrangement
- <20% blasts in blood and marrow
- At least one of:
- Dysplasia in ≥1 cell line
- Acquired clonal cytogenetic/molecular abnormality
- Persistent monocytosis ≥3 months with no other cause
For Essential Thrombocythemia 5:
- Platelets ≥450×10⁹/L
- Bone marrow showing increased mature megakaryocytes
- Presence of JAK2/CALR/MPL mutation (~80% of cases)
- Exclusion of other myeloid neoplasms (especially prefibrotic MF, PV, CML, MDS)
Critical Clinical Pitfalls
Pitfall 1: Ordering molecular panels prematurely
- Secondary causes (malignancy, inflammation, iron deficiency, splenectomy) account for most thrombocytosis cases 2
- Address these first to avoid unnecessary $3,000+ NGS panels
Pitfall 2: Missing CMML in "triple-negative" patients
- 10-15% of CMML patients lack JAK2/CALR/MPL mutations 4
- Rely on morphology, cytogenetics, and other molecular markers (TET2, SRSF2, ASXL1) 6
Pitfall 3: Confusing reactive monocytosis with CMML
- Sustained monocytosis (≥2 measurements over 3 months) significantly increases CMML probability 8
- Single monocytosis measurement in primary care has very low positive predictive value 8
Pitfall 4: Overlooking MPN with monocytosis
- Monocytosis in MPN patients indicates aggressive disease biology with inferior survival 1
- These patients are older, have leukocytosis, unfavorable cytogenetics, and higher symptom burden 1
Pitfall 5: Extreme thrombocytosis (>1500×10⁹/L)
- Paradoxically increases hemorrhage risk due to acquired von Willebrand syndrome 5
- Exercise caution with aspirin in this setting 4
Risk Stratification Once Diagnosis Made
If CMML diagnosed:
- Use IPSS or DIPSS-plus scoring (age, hemoglobin, WBC, blasts, cytogenetics) 3
- Median survival ranges 27-135 months depending on risk category 3
If ET diagnosed:
- Risk stratify by age >60 years and thrombosis history 4
- Consider triple A model (Age, Absolute neutrophil count, Absolute lymphocyte count) for survival prediction 5
If MPN with monocytosis:
- Higher risk profile with inferior survival compared to MPN without monocytosis 1
- More aggressive monitoring and earlier intervention consideration
When to Refer to Hematology
Immediate referral:
- Confirmed monocytosis >1×10⁹/L with thrombocytosis after excluding secondary causes
- Any blast cells on peripheral smear
- Unexplained cytopenias in other lineages
- Splenomegaly
Urgent referral (within 2 weeks):